REFERENCES

1., Arlington, Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Association. (2013), (5th ed.). American Psychiatric Publishing. ISBN 978-0890425558.

2., Aragao GF *et al.,* (2006), A possible mechanism for anxiolytic and antidepressant effects of alpha- and beta-amyrin from *Protium heptaphyllum* (Aubl.) March, Pharmacol Biochem Behav, 85(4), 827-34.

3., A.M.Douglas, e*t al.,* (2015), Prevalence of Depression and Depressive Symptoms Among Resident Physicians: A Systematic Review and Meta-analysis. 314.22., 2373–2383.

4., American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, (4th Ed), Text Revision: DSM-IV-TR. Washington, DC: American Psychiatric Publishing, Inc. ISBN 0-89042-025-4.

5., Boschloo L, Vogelzangs N, Van den Brink W, Smit JH, Veltman DJ, Beekman AT, Penninx BW (2012), Alcohol use disorders and the course of depressive and anxiety disorders, Br J Psychiatry.

6., Cardoso Vilela F, Soncini R, Giusti-Paiva A (2009), Anxiolytic-like effect of *Sonchus oleraceus* L. in mice, J Ethnopharmacol. 124(2)., 325-7.

7., C.G. Davey,M. Yücel,N.B.Allen, (2008). The emergence of depression in adolescence: Development of the prefrontal cortex and the representation of reward. Neuroscience & Biobehavioral Reviews 32., 1–19.

8., Davison, C. Gerald (2008), Abnormal Psychology. Toronto: Veronica Visentin. ISBN 978-0-470-84072-6.

9., Deng J, Zhou Y, Bai M, Li H, Li L (2010), Anxiolytic and sedative activities of *Passiflora edulis* (family Flavicarpa), J Ethnopharmacol, 128(1)., 148-53.

10., D.Saravane, *et al.,* (2009), Drawing up guidelines for the attendance of physical health of patients with severe mental illness. 3 (4)., 330–9.

11.,E.D.Murray, N.Buttner,B.H, Price Depression and Psychosis in Neurological Practice. In: Neurology in Clinical Practice, 6thed. ISBN 978-1437704341.

12.,Fakeye TO, Pal A, Khanuja SP (2008), Anxiolytic and sedative effects of extracts of *Hibiscus sabdariffa* Linn (family Malvaceae), Afr J Med Sci, 37(1)., 49-54.

13.,Grundmann O, Nakajima J, Seo S, Butterweck V (2007), Anti-anxiety effects of *Apocynum venetum* L. in the elevated plus maze test, J Ethnopharmacol, 110(3)., 406-11.

14.,G.O.Gabbard. Treatment of Psychiatric Disorders 2. Washington, DC: American Psychiatric Publishing. (3)1296.

15.,Griebel G. Belzung C et al(2001), Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125.,141-149.

16.,Garrett KM, Basmadjian G, Khan IA, Schaneberg BT, Seale TW (2003), Extracts of *kava* (*Piper methysticum*) induce acute anxiolytic-like behavioural changes in mice, Psychopharmacology (Berl), 170(1)., 33-41.

17.,Herrera-Ruiz M et al.,, (2008), Flavonoids from *Tilia americana* with anxiolytic activity in plus-maze test, J Ethnopharmacol, 118(2)., 312-7.

18.,H.Christine, D.N.Jeffrey, M.Tanja; HM.Andrew, B.N. Charles. (2001), The link between childhood trauma and depression: Insights from HPA axis studies in humans. Psychoneuroendocrinology 33,(6), Journal of Psychoneuroendocrinology. pp 693–710.

19.,Hattesohl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff H (2008), Extracts of *Valeriana officinalis* L. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties, Phytomedicine, (1-2)., 2-15.

20.,Herrera-Ruiz M et al., (2006), Antidepressant and anxiolytic effects of hydroalcoholic extract from *Salvia elegans*, J Ethnopharmacol, 107(1)., 53-8.

21.,Hellion-Ibarrola MC et al.,, (2006), the anxiolytic-like effects of *Aloysia polystachya (Griseb.)* Moldenke (Verbenaceae) in mice, J Ethnopharmacol, 105(3)., 400-8.

22.,Jung JW, Ahn NY, Oh HR, Lee BK, Lee KJ, Kim SY, Cheong JH, Ryu JH (2006), Anxiolytic effects of the aqueous extract of *Uncaria rhynchophylla*, J Ethnopharmacol, 108(2)., 193-7.

23.,J. Ormel, B.F.Jeronimus, M.Kotov, H.Riese, E.H.Bos, B.Hankin, (2013),"Neuroticism and common mental disorders: Meaning and utility of a complex relationship". Clinical Psychology Review. 686–697.

24.,J.LindertOS.Ehrenstein,R.Grashow,G.Gal,E.Braehler,MG.Weisskopf (2014), Sexual and physical abuse in childhood is associated with depression and anxiety over the life course: systematic review and meta-analysis. International Journal of Public Health. 59, (2)., 359–72.

25.,JK.Rustad, DL. Musselman,CB. Nemeroff. (2011),The relationship of depression and diabetes: Pathophysiological and treatment implications, Journal of Psychoneuroendocrinology. 36(9)., 1276–86.

26.,K.Pillemer,J. Suitor,S. Pardo,J.C. Henderson (2010). Mothers' Differentiation and Depressive Symptoms Among Adult Children. Journal of Marriage and Family, 72., 2-3

27.,Kuribara H, Weintraub ST, Yoshihama T, Maruyama Y (2003), An anxiolytic-like effect of *Ginkgo biloba* extract and its constituent, ginkgolide-A, in mice, J Nat Prod,66(10)., 1333-7.

28.,Lister RG (1987), The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92.,180-185.

29.,M.E.P.Seligman, E.F. Walker, D.L Rosenhan, (1989), Abnormal psychology. New York: W.W. Norton & Company (4th ed.)., ISBN 0393956989.

30.,M.Li, P.Fitzgerald, G. Rodin(2012), Evidence-based treatment of depression in patients with cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology ,30 (1)., 1187–96.

31.,N.Bouras, G Holt.(2007), Psychiatric and Behavioral Disorders in Intellectual and Developmental Disabilities ,Cambridge University Press,2.,27-29.

32.,VA Arlington, American Psychiatric Association (2013), Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Publishing. ISBN 978-0-89042-555-8.

33.,Nogueira E, Rosa GJ, Vassilieff VS (1998), Involvement of GABA(A)- benzodiazepine receptor in the anxiolytic effect induced by hexanic fraction of *Rubus brasiliensis*, J Ethnopharmacol, 61(2)., 119-26.

34.,P.Barker. (2003),Psychiatric and Mental Health Nursing: The Craft of Caring. London: Edward Arnold. ISBN 978-0-340-81026-2.

35.,Przegalinski E, Tatarczynska E, Chojnacka-Wójcik E (200), The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats, Neuropharmacology, 39(10)., 1858-64.

36.,Pellow S, Chopin P, File SE, Briley M.(1985), Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci Methods14.,149-167.

37.,Peng WH, Hsieh MT, Lee YS, Lin YC, Liao J (2000), Anxiolytic effect of seed of *Ziziphus jujuba* in mouse models of anxiety, J Ethnopharmacol, 72(3)., 435-41.

38.,Rabbani M, Sajjadi SE, Jafarian A, Vaseghi G (2005), Anxiolytic effects of *Salvia reuterana Boiss*. on the elevated plus-maze model of anxiety in mice, J. Ethnopharmacol, 101(1-3)., 100-3.

39.,Reginatto FH *et al.,* (2006), Evaluation of anxiolytic activity of spray dried powders of two South Brazilian *Passiflora* species, Phytother Res, 20(5)., 348-51.

40.,Rabbani M, Sajjadi SE, Zarei HR (2003), Anxiolytic effects of *Stachys lavandulifolia Vahl* on the elevated plus-maze model of anxiety in mice, J Ethnopharmacol, 89(2-3)., 271-6.

41.,Roychoudhury M, Kulkarni SK (1997), Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model, Methods Find Exp Clin Pharmacol, 19(2)., 107-11.

42.,Raupp IM *et al.,* (2008), Anxiolytic-like effect of chronic treatment with *Erythrina velutina* extract in the elevated plus-maze test, J Ethnopharmacol, 118(2)., 295-9.

43.,Schmidt, Peter (2005), Mood, Depression, and Reproductive Hormones in the Menopausal Transition. The American Journal of Medicine. 12.,54–58.

44.,Seo JJ *et al.,* (2007), Anxiolytic-like effects of obovatol isolated from *Magnolia obovata*: involvement of GABA/benzodiazepine receptors complex, Prog Neuropsychopharmacol Biol Psychiatry, 31(7)., 1363-9.

45.,Schmidt-Mutter C, Pain L, Sandner G, Gobaille S, Maitre M (1998), The anxiolytic effect of gamma-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil, Eur J Pharmacol, 342(1)., 21-7.

46.,Sampath C, Holbik M, Krenn L, Butterweck V (2011), Anxiolytic effects of fractions obtained from *Passiflora incarnata* L. in the elevated plus maze in mice, Phytother Res, 25(6)., 789-95.

47.,T. Rashid,I. Heider. Life Events and Depression. (2008), Annals of Punjab Medical College 2.,13-15.

48.,Tolardo R *et al.,* (2010), Evaluation of behavioural and pharmacological effects of *Hedyosmum brasiliense* and isolated sesquiterpene lactones in rodents, J Ethnopharmacol, 128(1)., 63-70.

49.,Viola H e*t al.,* (1994), Isolation of pharmacologically active benzodiazepine receptor ligands from *Tilia tomentosa* (Tiliaceae), J Ethnopharmacol, 44(1)., 47-53.

50.,V.A,Arlington. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders, (5th ed.)., 890-895.

51.,Vandenbogaerde A *et al.,* (2000), Evidence that total extract of *Hypericum perforatum* affects exploratory behaviour and exerts anxiolytic effects in rats, Pharmacol Biochem Behav, 65(4)., 627-33.

52.,Wieronska JM, Papp M, Pilc A (2001), Effects of anxiolytic drugs on some behavioural consequences in olfactory bul bectomized rats, Pol J Pharmacol, 53(5)., 517-25.

53.,W.V.Vieweg, Et al,. (May 2006), Posttraumatic Stress Disorder: Clinical Features, Pathophysiology, and Treatment. Am. J. Med. 119 (5)., 383–90.

54.,Zwolinski, Richard,CR. Zwolinski. Depression and Substance Abuse: The Chicken or the Egg? psychcentral.com

55.,Zanoli P, Avallone R, Baraldi M (2000), Behavioral characterisation of the flavonoids apigenin and chrysin, Fitoterapia, 71(1)., 117-23.